The Cigna Group — 2024 First-Quarter Form 10-Q Summary
Business context and reporting period
The filing covers the three months ended March 31, 2024. The Cigna Group operates through Evernorth Health Services, Cigna Healthcare, Other Operations and Corporate. Evernorth provides pharmacy benefit, specialty distribution and care-management services; Cigna Healthcare provides medical, dental and related insurance and administrative solutions.
Financial performance and key metrics
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Total revenues | $57.3 billion | $46.5 billion | 23% |
| Pharmacy revenues | $42.0 billion | $32.1 billion | 31% |
| Premiums | $11.6 billion | $11.0 billion | 5% |
| Income from operations | $2.3 billion | $2.0 billion | 12% |
| Shareholders’ net income (loss) | $(277) million | $1.267 billion | Declined |
| Diluted EPS | $(0.97) | $4.24 | Declined |
| Adjusted income from operations | $1.875 billion | $1.618 billion | 16% |
| Adjusted diluted EPS | $6.47 | $5.41 | 20% |
| Operating cash flow | $4.840 billion | $5.028 billion | Down $188 million |
GAAP results were adversely affected by a $1.8 billion impairment of the Company’s VillageMD equity investment, recorded in net realized investment losses. Net realized investment losses totaled $1.836 billion versus $56 million in the prior-year quarter. The effective tax rate increased to 368.4% from 18.4%, primarily because of a $427 million valuation allowance related largely to the equity-security impairment.
Adjusted income from operations benefited from higher earnings in both major operating segments. Evernorth’s pre-tax adjusted income increased 3% to $1.360 billion, while Cigna Healthcare’s increased 20% to $1.340 billion. Cigna Healthcare’s adjusted margin improved to 10.1% from 8.8%, and its medical care ratio improved to 79.9% from 81.3%. Evernorth’s adjusted margin declined to 2.9% from 3.6% because of client onboarding investments, including Centene, and investments in digital and care solutions.
Liquidity, debt and capital allocation
- Cash and cash equivalents were $8.439 billion at March 31, 2024, compared with $7.822 billion at December 31, 2023.
- Total debt was approximately $32.8 billion, consisting of $1.715 billion of short-term debt and $31.053 billion of long-term debt, versus approximately $30.9 billion at year-end 2023.
- The debt-to-capitalization ratio increased to 44.3% from 40.1%, primarily reflecting debt issuance and share repurchases.
- The Company issued $4.5 billion of senior notes in February 2024 and repurchased $1.8 billion of existing senior notes through tender offers.
- Operating cash flow was $4.840 billion; investing activities used $495 million and financing activities used $2.529 billion.
- The Company repurchased 10.1 million shares for approximately $3.4 billion during the quarter and paid $401 million in dividends. It expects to repurchase $5.0 billion of common stock in the first half of 2024.
- The February accelerated share repurchase agreements covered $3.2 billion of stock, with approximately 7.6 million shares initially delivered. Final settlement was expected in the second quarter of 2024.
- In April 2024, revolving credit commitments increased from $5.0 billion to $6.5 billion through a $5.0 billion five-year facility and a $1.5 billion 364-day facility. The Company had no borrowings under its revolving facilities at March 31.
Material changes versus the prior comparable period
- Revenue growth was driven primarily by higher Evernorth pharmacy volumes, including the Centene collaboration beginning January 1, 2024, branded-drug inflation and Specialty and Care Services growth.
- Pharmacy and other service costs rose 32%, broadly reflecting the increased pharmacy revenue base and Centene onboarding.
- Cigna Healthcare profitability improved due to pricing execution, affordability initiatives, business mix and expense discipline, despite a 1% decline in medical customers to 19.2 million.
- Unpaid claims and claim expenses increased 15% from December 31, 2023 to $5.863 billion. The increase reflected claim submission and payment disruptions related to a third-party cyber incident and normal stop-loss seasonality.
- The Company’s equity securities declined to $1.571 billion from $3.362 billion at year-end, primarily because of the VillageMD impairment.
- Other comprehensive loss increased to $460 million from $111 million, mainly due to changes in discount rates for long-duration insurance liabilities.
Guidance, outlook, commentary and risks
The Company stated that the final 2025 Medicare Advantage and Part D payment rates released by CMS were unchanged from the advance notice and are not expected to have a material impact on consolidated 2025 results. The filing does not provide a specific full-year earnings guidance figure in the supplied text.
The Company expects to complete the sale of its Medicare Advantage, Medicare Stand-Alone Prescription Drug Plans, Medicare and Other Supplemental Benefits and CareAllies businesses to Health Care Service Corporation in the first quarter of 2025, subject to regulatory approvals and other closing conditions. The transaction is expected to provide approximately $3.7 billion of transaction value, primarily cash. Assets held for sale totaled $6.354 billion and liabilities totaled $3.215 billion at March 31, 2024.
Key risks include medical-cost trends and claim-estimate variability, pharmacy pricing and manufacturer relationships, cyber and data-security incidents, regulatory and government-program changes, litigation and investigations, strategic-transaction execution, competition, inflation and interest rates, credit and reinsurance risk, capital-market access, and the Company’s significant debt obligations.
The Elevance litigation relating to Express Scripts remains subject to appeal of previously dismissed pricing claims. The filing states that the Company’s accrual is not material, but an adverse outcome could be material for a particular period and an aggregate loss range cannot currently be estimated.
Most important facts for investors to verify
- Whether the VillageMD impairment is nonrecurring or indicates further valuation pressure in the Company’s equity portfolio.
- The final number of shares and cash adjustment resulting from the $3.2 billion ASR agreements.
- Progress toward the HCSC transaction, including regulatory approval, closing timing and final proceeds.
- Medical-cost trends, claim development and the operational effects of the third-party cyber incident.
- Whether Evernorth’s lower adjusted margin improves after Centene onboarding and other planned investments.
- Debt maturities, refinancing costs and leverage following the February debt issuance and share repurchases.
- The outcome and potential financial exposure of the Elevance appellate proceedings and other legal or regulatory matters.